Overall rank 126 · Score 104 · 2025 Dec 1
Effects of oral semaglutide on cardiovascular outcomes: A systematic review and meta-analysis.
International journal of cardiology
Meta-analysisAI-recommended Tier ACardiovascular
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains quantitative evidence synthesis with a Tier A recommendation. No experimental retesting was performed or required.
Overall rank 127 · Score 104 · 2025 Nov 18
Cardiovascular Effects and Tolerability of GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of 99,599 Patients.
Journal of the American College of Cardiology
Meta-analysisAI-recommended Tier AHeart failure
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains quantitative evidence synthesis with a Tier A recommendation. No experimental retesting was performed or required.
Overall rank 128 · Score 104 · 2025 Aug
Comparative Efficacy and Tolerability of Tirzepatide Versus Semaglutide at Varying Doses for Weight Loss in Non-diabetic Adults With Obesity: A Network Meta-Analysis of Randomized Controlled Trials.
Cureus
Meta-analysisAI-recommended Tier ADiscontinuation & regain
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains quantitative evidence synthesis with a Tier A recommendation. No experimental retesting was performed or required.
Overall rank 129 · Score 104 · 2025 Sep-Oct
Efficacy and Safety of Once-Weekly IcoSema in Adults With Type 2 Diabetes: A Systematic Review and Meta-Analysis.
AACE endocrinology and diabetes
Meta-analysisAI-recommended Tier AOphthalmic
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains quantitative evidence synthesis with a Tier A recommendation. No experimental retesting was performed or required.
Overall rank 130 · Score 104 · 2025 Oct
Rebound or Retention: A Meta-Analysis of Weight Regain After the Discontinuation of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists and Other Anti-obesity Drugs.
Cureus
Meta-analysisAI-recommended Tier ADiscontinuation & regain
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains quantitative evidence synthesis with a Tier A recommendation. No experimental retesting was performed or required.
Overall rank 131 · Score 104 · 2025 Oct 30
Tirzepatide for adults living with obesity.
The Cochrane database of systematic reviews
Meta-analysisAI-recommended Tier AHeart failure
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains quantitative evidence synthesis with a Tier A recommendation. No experimental retesting was performed or required.
Overall rank 132 · Score 104 · 2025 Nov
Safety and Efficacy of Semaglutide in Patients With Chronic Kidney Disease, With or Without Type 2 Diabetes: A Systematic Review and Meta-Analysis.
Endocrinology, diabetes & metabolism
Meta-analysisAI-recommended Tier AKidney
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains quantitative evidence synthesis with a Tier A recommendation. No experimental retesting was performed or required.
Overall rank 133 · Score 104 · 2025 Dec 10
Effects of glucagon-like peptide-1 analogues on hard binary outcomes for patients at increased risk of cardiovascular events: a protocol for a systematic review with network meta-analysis and Trial Sequential Analysis.
BMJ open
Other human/translationalAI-recommended Tier DKidney
AI appraisal complete: Systematic-review protocol without synthesis results; corrected from completed meta-analysis. Evidence-class and Tier D recommendation updated from PubMed title/abstract, publication types, and registry metadata. No experimental retesting was performed or required.
Overall rank 134 · Score 104 · 2025 Dec 12
Impact of semaglutide use on glycemic and metabolic profile in adults with type 1 diabetes having overweight or obesity: A systematic review and meta-analysis.
Medicine
Meta-analysisAI-recommended Tier AType 2 diabetes
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains quantitative evidence synthesis with a Tier A recommendation. No experimental retesting was performed or required.
Overall rank 135 · Score 104 · 2023 Jan 31
Effect of the GLP-1 receptor agonist semaglutide on metabolic disturbances in clozapine-treated or olanzapine-treated patients with a schizophrenia spectrum disorder: study protocol of a placebo-controlled, randomised clinical trial (SemaPsychiatry).
BMJ open
Other human/translationalAI-recommended Tier DPediatric & adolescent
AI appraisal complete: Randomized-trial protocol without outcome results; corrected from completed randomized trial. Evidence-class and Tier D recommendation updated from PubMed title/abstract, publication types, and registry metadata. No experimental retesting was performed or required.
Overall rank 136 · Score 104 · 2023 Jun
Improvement of glycaemic control and treatment satisfaction by switching from liraglutide or dulaglutide to subcutaneous semaglutide in patients with type 2 diabetes: A multicentre, prospective, randomized, open-label, parallel-group comparison study (SWITCH-SEMA 1 study).
Diabetes, obesity & metabolism
Randomized trialAI-recommended Tier AType 2 diabetes
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains randomized comparative evidence with a Tier A recommendation. No experimental retesting was performed or required.
Overall rank 137 · Score 104 · 2023 May
Separate and combined effects of semaglutide and empagliflozin on kidney oxygenation and perfusion in people with type 2 diabetes: a randomised trial.
Diabetologia
Randomized trialAI-recommended Tier AKidney
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains randomized comparative evidence with a Tier A recommendation. No experimental retesting was performed or required.
Overall rank 138 · Score 104 · 2023 May
Effects of semaglutide and empagliflozin on oxygenation, vascular autoregulation, and central thickness of the retina in people with type 2 diabetes: A prespecified secondary analysis of a randomised clinical trial.
Journal of diabetes and its complications
Randomized trialAI-recommended Tier AOphthalmic
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains randomized comparative evidence with a Tier A recommendation. No experimental retesting was performed or required.
Overall rank 139 · Score 104 · 2023 Aug
Reducing BMI below the obesity threshold in adolescents treated with once-weekly subcutaneous semaglutide 2.4 mg.
Obesity (Silver Spring, Md.)
Randomized trialAI-recommended Tier APediatric & adolescent
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains randomized comparative evidence with a Tier A recommendation. No experimental retesting was performed or required.
Overall rank 140 · Score 104 · 2023 Oct
A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease.
Journal of hepatology
Randomized trialAI-recommended Tier AMASH & liver
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains randomized comparative evidence with a Tier A recommendation. No experimental retesting was performed or required.
Overall rank 141 · Score 104 · 2023 Aug 26
Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial.
Lancet (London, England)
Randomized trialAI-recommended Tier ASafety
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains randomized comparative evidence with a Tier A recommendation. No experimental retesting was performed or required.
Overall rank 142 · Score 104 · 2023 Aug 26
Efficacy and safety of once-daily oral semaglutide 25 mg and 50 mg compared with 14 mg in adults with type 2 diabetes (PIONEER PLUS): a multicentre, randomised, phase 3b trial.
Lancet (London, England)
Randomized trialAI-recommended Tier ASafety
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains randomized comparative evidence with a Tier A recommendation. No experimental retesting was performed or required.
Overall rank 143 · Score 104 · 2023 Sep 21
Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity.
The New England journal of medicine
Randomized trialAI-recommended Tier AHeart failure
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains randomized comparative evidence with a Tier A recommendation. No experimental retesting was performed or required.
Overall rank 144 · Score 103 · 2022 Mar
Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial.
The lancet. Diabetes & endocrinology
Randomized trialAI-recommended Tier AKidneySafetyDiscontinuation & regainPediatric & adolescent
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains randomized comparative evidence with a Tier A recommendation. No experimental retesting was performed or required.
Overall rank 145 · Score 103 · 2022 Oct
Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial.
Nature medicine
Randomized trialAI-recommended Tier AWeight loss & obesitySafetyDiscontinuation & regainPediatric & adolescent
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains randomized comparative evidence with a Tier A recommendation. No experimental retesting was performed or required.
Overall rank 146 · Score 103 · 2024 May
Potent incretin-based therapy for obesity: A systematic review and meta-analysis of the efficacy of semaglutide and tirzepatide on body weight and waist circumference, and safety.
Obesity reviews : an official journal of the International Association for the Study of Obesity
Meta-analysisAI-recommended Tier AWeight loss & obesityCardiovascularSafety
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains quantitative evidence synthesis with a Tier A recommendation. No experimental retesting was performed or required.
Overall rank 147 · Score 103 · 2024 Jul 1
Long-Term Efficacy and Safety of Once-Weekly Semaglutide for Weight Loss in Patients Without Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
The American journal of cardiology
Meta-analysisAI-recommended Tier AWeight loss & obesitySafetyDiscontinuation & regain
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains quantitative evidence synthesis with a Tier A recommendation. No experimental retesting was performed or required.
Overall rank 148 · Score 103 · 2024 Sep
Efficacy and safety of once-weekly subcutaneous semaglutide on weight loss in patients with overweight or obesity without diabetes mellitus-A systematic review and meta-analysis of randomized controlled trials.
Obesity reviews : an official journal of the International Association for the Study of Obesity
Meta-analysisAI-recommended Tier AWeight loss & obesitySafetyDiscontinuation & regain
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains quantitative evidence synthesis with a Tier A recommendation. No experimental retesting was performed or required.
Overall rank 149 · Score 103 · 2022 Jan
Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss.
Diabetes, obesity & metabolism
Randomized trialAI-recommended Tier AWeight loss & obesitySafetyDiscontinuation & regain
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains randomized comparative evidence with a Tier A recommendation. No experimental retesting was performed or required.
Overall rank 150 · Score 103 · 2022 Jan 11
Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial.
JAMA
Randomized trialAI-recommended Tier AWeight loss & obesitySafetyDiscontinuation & regain
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains randomized comparative evidence with a Tier A recommendation. No experimental retesting was performed or required.
Source registry generated 2026-09-17; AI appraisal completed 2026-09-22 under WPF-SGLT-AI-APPRAISAL-1.0. Humans resolve only the three displayed exceptions and record one accountable bundle publication decision. Records can appear in multiple domains; domain totals therefore overlap.